Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood had one of her busiest days on the trading floor in months on Tuesday. The co-founder, CEO, and ace stock picker ...
Crispr Therapeutics price target raised to $86 from $85 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares. With sufficient cash to support “years of development in ...